TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs for the use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does TaiRx, Inc. (6580) operate in?
TaiRx, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TaiRx, Inc. (6580) current stock price?
As of the latest data, TaiRx, Inc. stock price is NT$13.30, with a previous close of NT$13.30.
What is TaiRx, Inc. (6580) current market capitalization?
TaiRx, Inc. market cap is approximately 1.49 billion.
What is TaiRx, Inc. (6580) Earnings Per Share (EPS)?
The trailing EPS is -NT$2.00.
Does TaiRx, Inc. (6580) pay dividends?
No. TaiRx, Inc. does not pay a dividend.
What is TaiRx, Inc. (6580) beta (volatility) score?
TaiRx, Inc. has a beta of 0.364, indicating lower volatility than the overall market.
